氨甲酸,[[反-4-[[(1,1-二甲基乙氧基)羰基]氨基]环己基]甲基]-,苯基甲基酯 | 171846-13-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 氨甲酸,[[反-4-[[(1,1-二甲基乙氧基)羰基]氨基]环己基]甲基]-,苯基甲基酯
• 英文名称: trans-benzyl {4-[(tert-butoxycarbonyl)amino]cyclohexyl}methylcarbamate
• CAS: 171846-13-2
• 化学式: C₂₀H₃₀N₂O₄
• 分子量: 362.469
• InChiKey: OXVZXKRZKHZSGZ-JCNLHEQBSA-N

物化性质

• 沸点：
  519.0±29.0 °C(Predicted)
• 密度：
  1.12±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.0
• 重原子数：
  26.0
• 可旋转键数：
  5.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  76.66
• 氢给体数：
  2.0
• 氢受体数：
  4.0

反应信息

• 作为反应物：
  描述：

  氨甲酸,[[反-4-[[(1,1-二甲基乙氧基)羰基]氨基]环己基]甲基]-,苯基甲基酯 在 palladium dihydroxide 氢气 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 3.25h， 生成
  参考文献：
  名称：

  Structure–activity studies of cyclic ketone inhibitors of the serine protease plasmin: Design, synthesis, and biological activity

  摘要：

  Three series of cyclic ketone inhibitors were synthesized and evaluated against the serine protease plasmin. Peptide inhibitors that incorporated 3-oxotetrahydrofuran and 3-oxotetrahydrothiophene 1,1-dioxide groups had the highest activities. Alkylamino substituents, which were designed to bind in the S1 subsite of plasmin, were attached to the inhibitors. Compounds 5c and 5g, which incorporated 6-aminohexyl substituents, were found to be optimal and demonstrated IC50 values in the low micromolar range. Incorporating conformationally constrained peptide segments into the inhibitors did not improve their activities. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2006.08.040
• 作为产物：
  描述：

  trans-4-{[(phenylmethoxy)carbonylamino]methyl}cyclohexanecarboxylic acid 在 叠氮磷酸二苯酯 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 反应 20.5h， 生成 氨甲酸,[[反-4-[[(1,1-二甲基乙氧基)羰基]氨基]环己基]甲基]-,苯基甲基酯
  参考文献：
  名称：

  Structure–activity studies of cyclic ketone inhibitors of the serine protease plasmin: Design, synthesis, and biological activity

  摘要：

  Three series of cyclic ketone inhibitors were synthesized and evaluated against the serine protease plasmin. Peptide inhibitors that incorporated 3-oxotetrahydrofuran and 3-oxotetrahydrothiophene 1,1-dioxide groups had the highest activities. Alkylamino substituents, which were designed to bind in the S1 subsite of plasmin, were attached to the inhibitors. Compounds 5c and 5g, which incorporated 6-aminohexyl substituents, were found to be optimal and demonstrated IC50 values in the low micromolar range. Incorporating conformationally constrained peptide segments into the inhibitors did not improve their activities. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2006.08.040

文献信息

• Design and synthesis of 1,5- and 2,5-substituted tetrahydrobenzazepinones as novel potent and selective integrin α V β 3 antagonists
  作者：Andreas Kling、Gisela Backfisch、Jürgen Delzer、Hervé Geneste、Claudia Graef、Wilfried Hornberger、Udo E.W Lange、Arnulf Lauterbach、Werner Seitz、Thomas Subkowski

  DOI：10.1016/s0968-0896(02)00616-8

  日期：2003.4

  linking guanidine moiety and core, and modification of the guanidine mimetic. These efforts led to the identification of novel alpha(V)beta(3) inhibitors displaying potency in the subnanomolar range, selectivity versus alpha(IIb)beta(3) and functional efficacy in relevant cellular assays. A method for the preparation of enantiomerically pure derivatives was developed, and respective enantiomers evaluated

  设计和合成基于1，5-或2，5-取代的四氢苯并enza庚因核心的新型整联蛋白α（V）β（3）拮抗剂。通过alpha（V）beta（3）结合测定法确定各个化合物的体外活性，并将选定的衍生物提交功能细胞测定法进一步表征。通过修饰苯并ze庚酮核心，改变连接胍部分和核心的间隔基以及修饰胍模拟物获得SAR。这些努力导致鉴定出新颖的alpha（V）beta（3）抑制剂，其在亚纳摩尔范围内显示效力，相对于alpha（IIb）beta（3）的选择性以及相关细胞测定中的功能功效。开发了制备对映体纯衍生物的方法，并在体外评估了各个对映体。
• Pyrimidine derivatives useful as inhibitors of PKC-theta
  申请人：Barbosa J.M. Antonio

  公开号：US20060025433A1

  公开（公告）日：2006-02-02

  Disclosed are novel compounds of formula (I): wherein X, Y, R 1 , R 2 and R 3 are as defined herein, which are useful as inhibitors of PKC-theta and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC-theta, including immunological disorders and type II diabetes. This invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

  披露了公式(I)的新颖化合物：其中X、Y、R1、R2和R3如本文所述定义，它们作为PKC-theta的抑制剂是有用的，因此可用于治疗通过PKC-theta活性介导或维持的多种疾病和失调，包括免疫失调和II型糖尿病。本发明还涉及包含这些化合物的药物组合物、使用这些化合物治疗各种疾病和失调的方法、制备这些化合物的方法以及在这些过程中有用的中间体。
• Nanoparticular Inhibitors of Flavivirus Proteases from Zika, West Nile and Dengue Virus Are Cell-Permeable Antivirals
  作者：Barbara Schroeder、Peter Demirel、Christina Fischer、Enaam Masri、Stephanie Kallis、Lisa Redl、Thomas Rudolf、Silke Bergemann、Christoph Arkona、Christoph Nitsche、Ralf Bartenschlager、Jörg Rademann

  DOI：10.1021/acsmedchemlett.1c00515

  日期：2021.12.9

  several viral diseases including human immunodeficiency virus and hepatitis C virus infections due to the essential role of these enzymes in virus replication. In contrast, no antiviral therapy is available to date against flaviviral infections including those by Zika virus (ZIKV), West Nile virus (WNV), or dengue virus (DENV). Numerous potent inhibitors of flaviviral proteases have been reported; however

  由于这些酶在病毒复制中的重要作用，病毒蛋白酶已被确立为多种病毒性疾病（包括人类免疫缺陷病毒和丙型肝炎病毒感染）的药物靶标。相比之下，迄今为止还没有针对黄病毒感染的抗病毒疗法，包括寨卡病毒 (ZIKV)、西尼罗河病毒 (WNV) 或登革热病毒 (DENV) 感染。已经报道了许多有效的黄病毒蛋白酶抑制剂；然而，体外和细胞内活性之间仍然存在巨大差距，这可能是由于细胞对带电化合物的摄取量较低。在这里，我们提出了另一种抗病毒药物的纳米颗粒方法。拟肽抑制剂和细胞穿透肽与葡聚糖的结合产生了化学成分明确的纳米颗粒，这些纳米颗粒是黄病毒蛋白酶的有效抑制剂。肽-葡聚糖缀合物在无毒、低微摩尔甚至纳摩尔浓度下抑制细胞中的病毒复制和感染。因此，纳米颗粒抗病毒药物可能是开发广谱抗黄病毒药物的替代起点。
• NAPHTHYLPYRIMIDINE, NAPHTHYLPYRAZINE AND NAPHTHYLPYRIDAZINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM
  申请人：Pelletier Jeffrey Claude

  公开号：US20090054392A1

  公开（公告）日：2009-02-26

  The present invention relates to naphthylpyrimidine analogs, methods of making naphthylpyrimidine analogs, compositions comprising a naphthylpyrimidine analog, and methods for treating canonical Wnt-β-catenin cellular messaging system-related disorders comprising administering to a subject in need thereof an effective amount of a naphthylpyrimidine, naphthylpyrazine and naphthylpyridazine analog.

  本发明涉及萘基嘧啶类似物、制备萘基嘧啶类似物的方法、包含萘基嘧啶类似物的组合物以及治疗与经典Wnt-β-catenin细胞信息传递系统相关的疾病的方法，包括向需要治疗的受试者投予有效量的萘基嘧啶、萘基吡嗪和萘基吡啶类似物。
• Benzamide derivatives
  申请人：Imazaki Naonori

  公开号：US20050182040A1

  公开（公告）日：2005-08-18

  A compound represented by formula (1): wherein X is a single bond or a substituted or unsubstituted lower alkylene group; Z is a saturated or unsaturated monocyclic hydrocarbon ring group or the like; and each of R 1 , R 2 , R 3 and R 4 , which may be the same or different, is a hydrogen atom, a halogen atom, a nitro group, a cyano group, a carboxyl group, a substituted or unsubstituted alkyl group, or the like, a prodrug of said compound, or a pharmaceutically acceptable salt of said compound or prodrug has inhibitory effect on Rho kinase and hence is useful for treating diseases which are such that morbidity due to them is expected to be improved by inhibition of Rho kinase and secondary effects such as inhibition of the Na + /H + exchange transport system caused by the Rho kinase inhibition, for example, hypertension.

  一种由公式（1）表示的化合物：其中X是单键或取代或未取代的较低烷基链；Z是饱和或不饱和的单环烃基环或类似物；而每个R1、R2、R3和R4，可以相同也可以不同，是氢原子、卤素原子、硝基、氰基、羧基、取代或未取代的烷基或类似物，该化合物的前药，或该化合物或前药的药学上可接受的盐具有抑制Rho激酶的作用，因此可用于治疗因抑制Rho激酶而预计疾病的发病率得到改善的疾病，例如高血压，并且由于Rho激酶抑制所引起的Na+/H+交换转运系统的抑制等二次效应。